Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...

With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...

“In psoriatic arthritis and across the spectrum of axSpA ... Despite the hold-up, Bimzelx’s launch in psoriasis has been “the ...

The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...

The median time to discontinuation varied among the following biologics: Concomitant psoriatic arthritis (PsA) was more common in secukinumab users (24.4%) than in those receiving ustekinumab (12.2%).

New clinical data on Almirall’s biologics portfolio demonstrates further opportunities to positively impact patients and the ...

Despite being diagnosed with juvenile arthritis at age 2, as an adult Meaghan struggled to find a doctor who would take her ...

Access to adequate care for psoriasis is inconsistent across Europe and the condition remains misunderstood and undertreated.

Biological drugs target specific immune components to manage autoimmune diseases and cancer without suppressing the entire ...

Liebowitz said other inflammatory diseases such as psoriatic arthritis and lupus can mimic RA ... which are also used to treat rheumatoid arthritis." The first targeted biologic for RA, which is a ...